Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder

  • Karyopharm Therapeutics Inc KPTI announced updated data from Phase 1/2 trial of eltanexor (ATG-016) for patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS).
  • Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
  • Of the 15 patients evaluable for efficacy, 7 (47%) had marrow complete response (mCR), and 5 (33%) had stable disease (SD) for a total disease control rate of 80%.
  • In the 10 mg cohort (n=5), all patients derived clinical benefit with three patients (60%) reaching mCR and two patients (40%) reaching SD.
  • In the 20 mg cohort (n=10), 4 patients (40%) had mCR and 3 (30%) had SD.
  • Four patients had hematologic improvement (HI) and became transfusion-independent for at least eight weeks, including two patients with tri-lineage HI.
  • The overall survival (OS) for patients who reached mCR (n=7) was 11.86 months, compared to 8.67 months for patients who did not reach mCR (n=8).
  • Patients with the disease control (n=12) had numerically longer median overall survival (mOS) of 9.86 months vs. 3.15 months for patients with progressive disease.
  • Patients with HI had an mOS of 10.58 months.
  • Price Action: KPTI shares are up 6.42% at $10.04 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBlood DisordersBriefsmyelodysplastic syndrome
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!